Genes and response to chemotherapy for stage III colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial studies how your genes affect the way your body responds to a standard chemotherapy drug called fluorouracil (5-FU) for stage III colorectal cancer after surgery. Participating may help doctors tailor future treatment based on your genetic makeup.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have colorectal cancer that is stage III (cancer found in nearby lymph nodes, but not spread to distant organs).
- You must have had surgery to remove the cancer, and all visible cancer was removed.
- You must be 18 years or older, and be fit enough to carry out daily activities (ECOG score 0 or 1).
- Your blood counts and liver/kidney levels must be within certain limits.
- You cannot be pregnant or nursing, and you must use effective birth control if able to have children.
- You must not have certain heart problems, active infections, or other cancers in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether a special blood test (ctDNA methylation) can help decide the best chemotherapy after surgery for people at higher risk of colon cancer coming back. It may help spare some patients unnecessary treatment while aiming to improve outcomes for those likely to relapse.
This trial tests whether checking for cancer DNA in your blood (ctDNA) can help doctors decide if you need extra chemotherapy after surgery for stage III colon cancer. It aims to personalize treatment and avoid unnecessary chemo.
This study uses a blood test to check for tumor DNA after surgery, which may help doctors decide if you need additional chemotherapy. It is for people with stage 3 colorectal cancer that is removed by surgery.
This trial tests giving mFOLFIRINOX chemotherapy after curative surgery for people with high-risk stage III colon cancer. It aims to lower the chance that cancer comes back.
This study tests whether giving additional (adjuvant) chemotherapy based on a special blood test—circulating tumor DNA (ctDNA)—can lower the risk of colon cancer coming back. It targets people with stage II–III colon cancer whose blood test is positive for minimal residual disease (MRD) after completing standard chemo.
This trial tests whether a blood test that looks at cancer DNA can help decide whether you need “adjuvant” (extra) chemotherapy after colon cancer surgery. It may help some patients avoid unnecessary chemotherapy while still keeping the cancer from coming back.
Hear when a new Stage III Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.